Alteon Phase IIa ALT-711 data

ALT reported preliminary data from the first 17 patients in the 23-patient Phase IIa DIAMOND trial of its ALT-711 to treat diastolic heart failure (DHF). After 16 weeks, ALT said the compound significantly reduced left ventricular mass, a primary endpoint. ALT-711 also improved left ventricular diastolic filling and quality of life, which also were primary endpoints. The other primary endpoints of exercise tolerance and aortic stiffness "were not reportable," said ALT, because these measurements "proved to be more variable than anticipated." ALT was up $0.28 (14%) to $2.31 on Tuesday. ...